Antisense Oligonucleotide Therapies:The Promise and the Challenges from a Toxicologic Pathologist’s Perspective

Toxicologic Pathology

Volumn 43, Issue 1, 2015, Pages 78-89

  Frazier, Kendall S ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

drug development; mechanisms of toxicity; oligonucleotide; safety assessment; toxicologic pathology

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE;

ANTISENSE THERAPY; ARTICLE; HISTOPATHOLOGY; HUMAN; INFLAMMATION; LIVER TOXICITY; LYSOSOME; MICROSCOPY; NEPHROTOXICITY; NONHUMAN; PATHOLOGIST; PRIORITY JOURNAL; THROMBOCYTOPENIA; TOXICOLOGIC PATHOLOGIST; VASCULITIS; ANIMAL; DRUG DEVELOPMENT; PATIENT SAFETY; PROCEDURES; TOXICITY TESTING;

ANIMALS; DRUG DISCOVERY; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; PATIENT SAFETY; TOXICITY TESTS;

EID: 84921724922     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623314551840     Document Type: Article

References (68)

1. Agrawal S. Kandimalla E. R. (2004). Antisense and siRNA as agonists of toll-like receptors. Nat Biotech 22, 1523–37.
2. A., Akinc, W., Querbes, S., De, J., Qin, M., Frank-Kamenetsky, K.N., Jayaprakash, M., Jayaraman, K.G., Rajeev, W.L., Cantley, J.R., Dorkin, J.S., Butler, L., Qin, T., Racie, A., Sprague, E., Fava, A., Zeigerer, M.J., Hope, M., Zerial, D.D.Y., Sah, K., Fitzgerald, M.A., Tracy, M., Manoharan, V., Koteliansky, A., de Fougerolles, M.A., Maier, Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms, Mol Ther, (2010), 18, 1357-1364
3. Alexander N. J. Clarkson T. B. Fulgham D. L. (1985). Circulating immune complexes in cynomolgus macaques. Lab Anim Sci 35, 465–68.
4. Burdick A. D. Sciabola S. Srinivasa R. Mantena B. D. Hollingshead T. Stanton R. Warneke J. A. Zeng M. Martsen E. Medvedev A. Makarov S. S. Reed L. A. Davis J. W. II Whitely L. O. (2014). Sequence motifs associated with hepatotoxicity of locked nucleic acid—modified antisense oligonucleotides. Nucleic Acids Res 42, 1–10.
5. Burel S. A. Han S.-R. Lee H.-S. Norris D. A. Lee B.-S. Machemer T. Park S. Y. Zhou T. He G. Kim Y. MacLeod A. R. Monia B. P. Lio S. Kim T. W. Henry S. P. (2013). Preclinical evaluation of the toxicologic effects of a novel constrained ethyl antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys. Nucleic Acid Ther 23, 213–27.
6. Burel S. A. Machemer T. Ragone F. L. Kato H. Cauntay P. Greenlee S. Salim A. Gaarde W. A. Hung G. Peralta R. Freier S. M. Henry S. P. (2012). Unique O-methoxyethyl ribose-DNA chimeric oligonucleotide induces an atypical melanoma differentiation-associated gene 5-dependent induction of type I interferon response. J Pharmacol Exp Ther 342, 150–62.
7. Cattaneo M. Lecchi A. (2007). Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin. J Thromb Haemost 5, 577–82.
8. Choi S.-S. Chung E. Jung Y.-J. (2010). Newly identified CpG ODNs, M5-30 and M6-395, stimulate mouse immune cells to secrete TNF-α and enhance Th1-mediated immunity. J Microbiol 48, 512–17.
9. Choksi A. N. Poonawalla T. Wilkerson M. G. (2010). Nanoparticles: A closer look at their dermal effects. J Drugs Dermatol 9, 475–81.
10. Cuddihy A. R. Li S. Tam N. W. Wong A. H. Taya Y. Abraham N. Bell J. C. Koromilas A. E. (1999). Doublestranded-RNA-activated protein kinase PKR enhances transcriptional activation by tumor suppressor p53. Mol Cell Biol 19, 2475–84.
11. Dean N. M. Bennet C. F. (2003). Antisense oligonucleotide-based therapeutics for cancer. Oncogene 22, 9087–96.
12. Dias N. Stein C. A. (2002). Antisense oligonucleotides: Basic concepts and mechanisms. Mol Cancer Ther 1, 347–55.
13. EMA (European Medicines Agency). (2012). Refusal of the marketing authorization for Kynamro (mipomersen). EMA/792736/2012; EMEA/H/C/002429.
14. Engelhardt J. Fant P. Guionaud S. Henry S. P. Leach M. Louden C. Scicchitano M. S. Weaver J. L. Zabka T. S. Frazier K. S. (2014). Drug induced vascular injury associated with non-small molecule therapeutics in preclinical development: Part 2. Antisense oligonucleotide associated vasculitis. (Submitted October 2014, Toxicol Pathol).
15. Farman C. A. Kornbrust D. J. (2003). Oligodeoxynucleotide studies in primates: Antisense and immune stimulatory indications. Toxicol Pathol 31, 119S–22S.
16. Fiset P.-O. Gounni A. S. (2001). Antisense oligonucleotides: Problems with use and solutions. Rev Biol & Biotechnol 1, 27–33.
17. FDA (Food & Drug Administration). (2012). EMDAC clinical briefing document, NDA 203568, Mipomersen Sodium Injection 200 mg/mL. Endocrinologic and metabolic drugs advisory committee meeting.
18. Frank-Kamenetsky M. Grefhorst A. Anderson N. N. Racie T. S. Bramlage B. Akinc A. Butler D. Charisse K. Dorkin R. Fan Y. Gamba-Vitalo C. Hadwiger P. Jayaraman M. John M. Jayaprakash K. N. Maier M. Nechev L. Rajeev K. G. Read T. Röhl I. Soutschek J. Tan P. Wong J. Wang G. Zimmermann T. de Fougerolles A. Vornlocher H. P. Langer R. Anderson D. G. Manoharan M. Koteliansky V. Horton J. D. Fitzgerald K. (2008). Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA 105, 11915–20.
19. Frazier K. S. Seely J. C. (2013). Urinary system. In Toxicologic Pathology: Preclinical Safety Assessment (Sahota P. S. Popp J. A. Hardisty J. F. Gopinath C., eds.), pp. 421–84. CRC press/TaylorFrancis pub, Boca Raton, FL.
20. Frazier K. S. Seely J. C. Hard G. C. Betton G. C. Burnett R. Nishikawa A. Nakatsuji S. Durchfeld-Meyer B. Bube A. (2012). Proliferative and nonproliferative lesions in the rodent urinary system. Toxicol Pathol 40, 14–86.
21. Frazier K. S. Sobry C. Derr V. Adams M. J. Den Besten C. De Kimpe S. Francis I. Gales T. L. Maguire S. R. Mirabile R. C. Mullins D. Palate B. Ponstein-Simarro Doorten Y. Ridings J. E. Scicchitano M. S. Silvano J. Woodfine J. (2014). Species specific inflammatory responses as a primary component for the development of glomerular lesions in mice and monkeys following chronic administration of a second generation antisense oligonucleotide. Toxicol Pathol 42, 923–35.
22. Geuze H. J. Slot J. W. Strous G. J. Schwartz A. L. (1983). The pathway of the asialoglycoprotein-ligand during receptor-mediated endocytosis: A morphological study with colloidal gold/ligand in the human hepatoma cell line, Hep G2. Eur J Cell Biol 32, 277–87.
23. Greinacher A. Gopinadhan M. Gunther J. U. Omer-Adam M. A. Strobel U. Warkentin T. E. Papastavrou G. Weitschies W. Helm C. A. (2006). Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscler Thromb Vasc Biol 26, 2386–93.
24. Hagedorn P. H. Yakimov V. Ottosen S. Kammler S. Nielsen N. F. Hog A. M. Hedtjarn M. Meldgaard M. Møller M. R. Orum H. Koch T. Lindow M. (2013). Hepatotoxic potential of therapeutic oligonucleotides can be predicted from their sequence and modification pattern. Nucleic Acid Ther 23, 302–10.
25. Hajishengallis G. Lambris J. D. (2010). Crosstalk pathways between toll-like receptors and the complement system. Trends Immunol 31, 154–63.
26. Hartmann G. Krug A. Waller-Fontaine K. Endres S. (1996). Oligodeoxynucleotides enhance lipopolysaccharide-stimulated synthesis of tumor necrosis factor: Dependence on phosphorothioate modification and reversal by heparin. Mol Med 2, 429–38.
27. Heikenwalder M. Polymenidou M. Junt T. Sigurdson C. Wagner H. Akira S. Zinkernagel R. Henry S. P. Beattie G. Yeh G. Chappel A. Giclas P. Mortari A. Jagels M. A. Kornburst D. J. Levin A. A. (2002). Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide. Int Immunopharmacol 2, 1657–66.
28. Henke E. Perk J. Vider J. de Candia P. Chin Y. Solit D. B. Ponomarev V. Cartegni L. Manova K. Rosen N. Benezra R. (2008). Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo. Nat Biotechnol 26, 91–100.
29. Henry S. P. Beattie G. Yeh G. Chappel A. Giclas P. Mortari A. Jagels M. A. Kornburst D. J. Levin A. A. (2002). Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide. Int Immunopharmacol 2, 1657–66.
30. Henry S. P. Giclas P. C. Leeds J. Pangburn M. Auletta C. Levin A. A. Kornbrust D. J. (1997). Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: Potential mechanism of action. J Pharmacol Exp Ther 281, 810–6.
31. Henry S. P. Kim T.-W. Kramer-Stickland K. Zanardi T. A. Fey R. A. Levin A. A. (2008). Toxicologic properties of 2′-methoxyethyl chimeric antisense inhibitors in animals and man. In Antisense Drug Technology: Principles, Strategies and Applications, 2nd ed. (Crooke S. T., ed.), pp. 327–63. CRC Press, Carlsbad, CA.
32. Henry S. P. Templin M. V. Gillett N. Rojko J. Levin A. A. (1999). Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1. Toxicol Pathol 27, 95–100.
33. Herrington W. G. Talbot D. C. Lahn M. M. Brandt J. T. Callies S. Nagle R. Winearls C. G. Roberts I. S. (2011). Association of long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 with reversible kidney injury in a patient with metastatic melanoma. Am J Kidney Dis 57, 300–3.
34. Hutvagner G. Zamore P. D. (2002). A microRNA in a multiple-turnover RNAi enzyme complex. Science 297, 2056–60.
35. Jaax M. E. Krauel K. Marschall T. Brandt S. Gansler J. Fürll B. Appel B. Fischer S. Block S. Helm C. A. Müller S. Preissner K. T. Greinacher A. (2013). Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4. Blood 122, 272–81.
36. Jackson A. L. Burchard J. Schelter J. Chau B. N. Cleary M. Lim L. Linsley P. S. (2006). Widespread siRNA off-target transcript silencing mediated by seed region sequence complementarity. RNA 12, 1179–87.
37. P., Jarver, T., Coursindel, S.E., Andaloussi, C., Godfrey, M.M.A., Wood, M.J., Gait, Peptide-mediated cell and in vivo delivery of antisense oligonucleotides and siRNA, Mol Ther Nucleic Acids, doi:10.1038/mtna.2012.18, (2012), 1, e27
38. Kakiuchi-Kiyota S. Koza-Taylor P. H. Mantena S. R. Nelms L. F. Enayetallah A. E. Hollingshead B. D. Burdick A. D. Reed L. A. Warneke J. A. Whiteley L. O. Ryan A. M. Mathialagan N. (2014). Comparison of hepatic transcription profiles of locked ribonucleic acid antisense oligonucleotides: Evidence of distinct pathways contributing to non-target mediated toxicity in mice. Toxicol Sci 138, 234–48.
39. Krieg A. M. (1998). Leukocyte stimulation by oligodeoxynucleotides. In Applied Antisense Oligonucleotide Technology (Stein C. A. Krieg A. M., eds.), pp. 431–48. Wiley-Liss, New York.
40. Krieg A. M. (1999). Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim Biophys Acta 1489, 107–16.
41. Krieg A. M. (2002). CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20, 709–60.
42. Kwoh J. T. 2008. An overview of the clinical safety experience of first- and second-generation antisense oligonucleotides. In Antisense Drug Technology: Principles, Strategies, and Applications (Crooke S. T., ed.), pp. 365–99. CRC Press, Boca Raton, FL.
43. Larsen H. J. Bentin T. Nielsen P. E. (1999). Antisense properties of peptide nucleic acid. Biochim Biophys Acta 1489, 159–66.
44. Levin A. A. Henry S. P. (2008). Toxicology of oligonucleotide therapeutics and understanding the relevance of toxicities. In Preclinical Safety Evaluation of Biopharmaceuticals. A Science-based Approach to Facilitating Clinical Trials (Cavagnaro J. A., ed.), pp. 538–74. Wiley, Hoboken, NJ.
45. Lindow M. Vornlocher H. P. Riley D. Kornbrust D. J. Burchard J. Whiteley L. O. Kamen J. Thompson J. D. Nochur S. Younis H. Bartz S. Parry J. Ferrari N. Henry S. P. Levin A. A. (2012). Assessing unintended hybridization-induced biological effects of oligonucleotides. Nat Biotechnol 30, 920–23.
46. Marquis J. K. Grindel J. M. (2000). Toxicological evaluation of oligonucleotide therapeutics. Curr Opin Mol Ther 2, 258–63.
47. Monteith D. K. Horner M. J. Gillett N. A. Butler M. Geary R. Burckin T. Ushiro-Watanabe T. Levin A. (1999). Evaluation of the renal effects of an antisense phosphorothioate oligodeoxynucleotide in monkeys. Toxicol Pathol 27, 307–17.
48. Monteith D. K. Levin A. A. (1999). Synthetic oligonucleotides: The development of antisense therapeutics. Toxicol Pathol 27, 8–13.
49. Obad S. dos Santos C. O. Petri A. Heidenblad M. Broom O. Ruse C. Fu C. Lindow M. Stenvang J. Straarup E. M. Hansen H. F. Koch T. Pappin D. Hannon G. J. Kauppinen S. (2011). Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 43, 371–78.
50. Ozbaş-Turan S. Akbuğa J. Sezer A. D. (2010). Topical application of antisense oligonucleotide-loaded chitosan nanoparticles to rats. Oligonucleotides 20, 147–53.
51. Prakash T. P. Graham M. J. Yu J. Carty R. Low A. Chappell A. Schmidt K. Zhao C. Aghajan M. Murray H. F. Riney S. Booten S. L. Murray S. F. Gaus H. Crosby J. Lima W. F. Guo S. Monia B. P. Swayze E. E. Seth P. P. (2014). Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acid Res 42, 8796–807.
52. Ravindran C. Jeng Y.-C. Liang S.-M. (2010). CpG-ODNs induces up-regulated expression of chemokine CCL9 in mouse macrophages and microglia. Cellular Immunol 260, 113–18.
53. Richardt-Pargmann D. Vollmer J. (2009). Stimulation of the immune system by therapeutic antisense oligodeoxynucleotides and small interfering RNAs via nucleic acid receptors: How to avoid Immune Activation. Oligonucleotide Therapeutics: Ann NY Acad Sci 1175, 40–54.
54. Scacheri P. C. Rozenblatt-Rosen O. Caplen N. J. Wolfsberg T. G. Umayam L. Lee J. C. Hughes C. M. Shanmugam K. S. Bhattacharjee A. Meyerson M. Collins F. S. (2004). Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc Natl Acad Sci USA 101, 1892–7.
55. Senn J. J. Burel S. Henry S. P. (2005). Non-CpG-containing antisense 2_-methoxyethyl oligonucleotides activate a proinflammatory response independent of toll-like receptor 9 or myeloid differentiation factor 88. J Pharmacol Exper Therapeutics 314, 972–9.
56. Stanton R. Sciabola S. Salatto C. Weng Y. Moshinsky D. Little J. Walters E. Kreeger J. DiMattia D. Chen T. Clark T. Liu M. Qian J. Roy M. Dullea R. (2012). Chemical modification study of antisense gapmers. Nucleic Acid Ther 22, 344–59.
57. Stein C. A. (1997). Controversies in the cellular pharmacology of oligodeoxynucleotides. Ciba Found Symp 209, 79–89.
58. Summerton J. (2004). Morpholinos and PNAs compared. Lett Pep Sci 10, 215–36.
59. Swayze E. E. Siwkowski A. M. Wancewicz E. V. Migawa M. T. Wyrzykiewicz T. K. Hung G. Monia B. P. Bennett C. F. (2007). Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res 35, 687–700.
60. van Poelgeest E. P. Swart R. M. Betjes M. G. Moerland M. Weening J. J. Tessier Y. Hodges M. R. Levin A. A. Burggraaf J. (2013). Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9. Am J Kidney Dis 62, 796–800.
61. Vickers T. A. Lima W. F. Nichols J. G. Crooke S. T. (2007). Reduced levels of Ago2 expression result in increased siRNA competition in mammalian cells. Nucleic Acids Res 35, 6598–610.
62. Wahlestedt C. Salmi P. Good L. Kela J. Johnsson T. Hokfelt T. Broberger C. Porreca F. Lai J. Ren K. Ossipov M. Koshkin A. Jakobsen N. Skouv J. Oerum H. Jacobsen M. H. Wengel J. (2000). Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Nat Acad Sci 97, 5633–38.
63. Wang S. Zhang X. Yu B. Lee R. J. Lee L. J. (2010). Targeted nanoparticles enhanced flow electroporation of antisense oligonucleotides in leukemia cells. Biosens Bioelectron 26, 778–83.
64. Waters J. S. Webb A. Cunningham D. Clarke P. A. Raynaud F. di Stefano F. Cotter F. E. (2000). Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin’s lymphoma. J Clin Oncol 18, 1812–23.
65. Younis H. S. Young R. Wilkens D. Tabor M. Henry S. P. (2013). Oligonucleotides modulate ADP-dependent platelet activation in cynomolgus monkey but not in human whole blood. Poster presentation at DIA/FDA oligonucleotide conference, Washington, DC, September 2013.
66. Yuen A. R. Halsey J. Fisher G. A. Holmlund J. T. Geary R. S. Kwoh J. T. Dorr A. Sikic B. (1999). Phase I study of an antisense oligonucleotide to protein kinase C-α (ISIS 3521/CGP 64128A) in patients with cancer. Clin Canc Res 5, 3357–63.
67. Zamore P. D. Tuschl T. Sharp P. A. Bartel D. P. 2000. RNAi: Double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101, 25–33.
68. Zhao Z. Tuakli-Wosornu Y. Lagace T. A. Lisa K. Grishin N. V. Horton J. D. Cohen J. C. Hobbs H. H. (2006). Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 79, 514–23.